Fact-checked by Grok 2 weeks ago

Alkem Laboratories

Alkem Laboratories Limited is an Indian multinational pharmaceutical company headquartered in , , specializing in the research, development, , and distribution of generic and specialty pharmaceutical products as well as nutraceuticals. Founded in 1973 by brothers and Basudeo N. Singh, the company began as a pharmaceutical distribution venture before establishing its first unit in 1978 and evolving into a major player in the industry. Today, Alkem operates 18 facilities, including 17 in and one in the United States, maintains five global R&D centers with over 500 scientists, and offers a portfolio exceeding 800 brands, including leading products like Clavam, , Pan-D, and Taxim-O focused on acute therapies such as anti-infectives and . With a of more than 21,000 employees, Alkem reported consolidated revenues of ₹129,645 million for the 2024-25 and has expanded its business footprint to over 40 countries, including key markets , , and . The company ranks among the top 10 pharmaceutical firms by , standing at ninth place with a market cap of approximately ₹63,000 as of mid-2025, underscoring its commitment to quality healthcare and innovation.

Overview

Corporate profile

Alkem Laboratories Limited is a public limited multinational pharmaceutical company headquartered at Alkem House, Senapati Bapat Marg, Lower Parel, , , . It is listed on the (BSE) under the code 539523 and on the National Stock Exchange (NSE) under the symbol ALKEM. As of March 31, 2025, the company employs 22,833 people globally (including workers). The company's core business encompasses the development, manufacturing, and marketing of generic drugs, branded formulations, active pharmaceutical ingredients (), and nutraceuticals. Alkem operates 18 facilities and maintains a portfolio of over 800 brands, including prominent ones such as Taxim and Clavam. Alkem has a global footprint in over 40 countries, with its primary market in and significant exports to the , , , , , and . As of March 31, 2025, the company's consolidated total assets stood at ₹17,691 (US$2.1 billion).

Leadership

Alkem Laboratories' leadership transitioned following the passing of its founder, , on July 27, 2019, with the Singh family inheriting the majority stake and Basudeo N. Singh, the co-founder, assuming the role of Executive Chairman to provide strategic oversight. , son of the founder, was appointed Managing Director in October 2017, overseeing domestic and international operations with over 18 years of experience within the organization; he holds a B.Com degree and has driven the company's expansion in generics and branded formulations. Dr. serves as since September 2023, bringing more than 20 years of pharmaceutical expertise across acute, chronic, and consumer healthcare segments; he earned an MBBS from the , , and a doctorate from the University of Delhi. The Board of Directors comprises 12 members as of 2025, including six executive directors from the promoter Singh family—Basudeo N. Singh (Executive Chairman), Sandeep Singh (Managing Director), Mritunjay Kumar Singh (Executive Director), Madhurima Singh (Executive Director), Sarvesh Singh (Executive Director), and Srinivas Singh (Executive Director)—alongside six independent non-executive directors: Narendra Kumar Aneja, Sujjain Talwar, Rajeev Kher, Ranjal Laxmana Shenoy, Neela Bhattacherjee, and Diwakar Gupta (appointed in June 2025). Basudeo N. Singh, a co-founder since 1973 and former economics professor from Bihar, guides long-term strategy with a focus on innovation and global reach, having transformed the initial Rs 5 lakh venture into a multibillion-dollar enterprise. Key board committees ensure robust oversight, with the Audit Committee chaired by independent director Narendra Kumar Aneja and including Sandeep Singh, Mritunjay Kumar Singh, Ranjal Laxmana Shenoy, Rajeev Kher, and Diwakar Gupta to monitor financial reporting and compliance. The Nomination and Remuneration Committee, led by Ranjal Laxmana Shenoy, comprises Basudeo N. Singh, Sujjain Talwar, and Neela Bhattacherjee, focusing on director appointments and performance evaluations. Other committees include the Stakeholders' Relationship Committee (chaired by Sujjain Talwar), Risk Management Committee (chaired by Mritunjay Kumar Singh), and Corporate Social Responsibility and Sustainability Committee (chaired by Madhurima Singh). Alkem Laboratories maintains strong practices in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including regular board meetings (at least four annually), familiarization programs, and transparent related-party transaction policies. initiatives are integrated through an policy overseen by the , which addresses environmental risks, and the CSR , aligning efforts with UN via projects in and community health.

History

Founding and early development

Alkem Laboratories was incorporated as a on August 8, 1973, in , , under the , by brothers and Basudeo N. Singh, with an initial equity allotment of 50 shares at ₹100 each. The registered office was later shifted to , , in 2007. Originally established as a healthcare firm based in , the company focused on the and distribution of pharmaceutical products, including basic generic drugs, to address affordable healthcare needs in . , drawing from his prior experience in , envisioned transforming the sector dominated by international brands, while Basudeo Singh contributed through distribution networks. In its early years, Alkem emphasized gradual investments in to support its formulations business, prioritizing the domestic market amid India's evolving regulatory landscape. The Patents Act, 1970, which limited patents to processes rather than products, enabled Indian firms like Alkem to reverse-engineer and produce affordable generics, though the company faced challenges in building manufacturing capabilities during the 1970s and 1980s. Key hurdles included stringent compliance with the Drugs and Cosmetics Act of 1940, market competition from multinational players, and limited infrastructure, which delayed scaling operations. By 1978, Alkem commissioned its first manufacturing plant in Taloja, , marking the shift from marketing to production. The company's initial product launches centered on anti-infectives, a critical therapeutic area for India's healthcare needs, with brands like Taxim emerging as early successes in the domestic generic segment. By 1992, Alkem established additional facilities, including the Mandwa plant in , enhancing production capacity for formulations and active pharmaceutical ingredients. These developments were punctuated by operational setbacks, such as a labor lockout at the Taloja facility from December 1993 to May 1994, which tested the company's resilience under the regulatory oversight of the . In the late 1990s, Alkem began preparations for public listing, becoming a deemed on October 26, 1988, under Section 43A(2) of the Companies Act, and undertaking equity restructuring, including a share subdivision in 1994 and a bonus issue of 83,850 shares in 1995. This culminated in the company's (IPO) in November 2015. This transition laid the groundwork for broader growth, while maintaining a focus on domestic generics before venturing into international markets like the in the early .

Key milestones and growth

In 2003, Alkem Laboratories established its first research and development (R&D) facility in Taloja, , dedicated to developing Abbreviated New Drug Applications (ANDAs) for the U.S. market, marking a pivotal step toward international expansion. By 2006, the company's flagship brand Taxim achieved a significant , surpassing ₹1,000 million in domestic sales, underscoring its growing dominance in the Indian pharmaceutical sector. In 2007, Alkem filed its inaugural ANDA for Amlodipine besylate, a key , which received U.S. (FDA) approval in 2009, enabling entry into the lucrative generic market abroad. The year 2014 brought further success with the Clavam brand, an anti-infective formulation, exceeding ₹2,000 million in sales; concurrently, Alkem ventured into the nutraceuticals segment to diversify its portfolio beyond traditional pharmaceuticals. Post-2019, Alkem advanced initiatives through subsidiaries and partnerships, including the launch of Connect2Clinic, a platform for streamlining healthcare practice management and telemedicine services. The company also committed to goals, such as achieving certification for over 75% of its sites by 2025 and enhancing environmental protections under its policy, reflecting a broader focus on responsible growth. This trajectory propelled Alkem to rank among the top 10 pharmaceutical companies in India by market capitalization in 2025, with a valuation of approximately ₹63,000 crore, solidifying its position as a leading generics player.

Operations

Manufacturing and facilities

Alkem Laboratories maintains a robust manufacturing infrastructure consisting of 18 facilities, with 17 located in India across states including Himachal Pradesh (Baddi), Gujarat (Mandva and Ankleshwar), Maharashtra (Pune), and others, and one in the United States. These sites form the backbone of the company's production capabilities, enabling efficient scaling for domestic and international markets. The facilities specialize in diverse , including oral solids such as tablets and capsules, injectables, for eye care products, and active pharmaceutical (APIs). Five of these facilities have obtained approvals from the Food and Drug Administration (US FDA), the Therapeutic Goods Administration (TGA) of , and the Medicines and Healthcare products Regulatory Agency (MHRA) of the , ensuring compliance with stringent global standards. In terms of capacity, the network supports large-scale production, bolstered by a exceeding 3,000 dedicated production personnel, and has seen expansions in sterile injectables post-2020 to address rising demand in complex formulations. For instance, the injectables division was enhanced to improve output for and segments. In 2025, acquired a manufacturing facility in and inaugurated a new biologics facility in , USA, through subsidiary Enzene Biosciences, with commercial operations expected by mid-fiscal year 2026. Quality control is prioritized through comprehensive measures, with all facilities adhering to Good Manufacturing Practices (WHO-GMP). Up to 2025, investments in , including electronic logbooks and batch management systems, have streamlined operations and enhanced . A technical training center at the Daman facility further supports ongoing skill development. The emphasizes reliable sourcing, primarily from domestic Indian suppliers supplemented by imports from key global partners in the United States, , and , while maintaining low direct exposure to high-risk regions like and holding one-to-two months of inventory for resilience.

Product portfolio and therapeutic areas

Alkem Laboratories offers a comprehensive portfolio of over 800 branded generics encompassing more than 1,500 stock-keeping units (SKUs), with a focus on both acute and chronic healthcare needs. The company's formulations span 705 distinct products, including key brands such as Taxim, a leading , and Clavam, a prominent combination for bacterial infections. Among these, 18 brands rank within India's top 300 pharmaceutical brands by the Indian Pharmaceutical Market (IPM) as of the fiscal year 2023–24, highlighting Alkem's strong domestic presence in high-volume segments. The portfolio is heavily weighted toward acute therapies, with anti-infectives constituting approximately 36.1% of contributions and maintaining a market-leading 12.9% share in as of the fiscal year 2023–24, where the company has held the top position for over 15 years. Other core therapeutic areas include (10.6% contribution), and analgesics (8.0%), and vitamins, minerals, and nutraceuticals (7.8%) as of the 2023–24, where Alkem ranks second in the IPM. In chronic segments, the company addresses (12.5% contribution) and anti-diabetics (8.9%), with overall chronic therapies accounting for 18% of the prescription portfolio as of the 2023–24 and showing accelerated growth. This diversified focus positions Alkem as a leader in acute therapies across , outperforming the broader market in key sub-segments. In the United States, Alkem's offerings center on generic drugs through its subsidiary Ascend Laboratories, with over 159 Abbreviated New Drug Applications (ANDAs) approved by the U.S. (FDA) as of 2024-25, enabling distribution via major pharmacy chains and wholesalers. Notable U.S. products include specialty generics like Clindac-A, acquired from in 2013 and integrated into the portfolio for treatment. Post-2020 innovations have expanded the portfolio into and over-the-counter (OTC) categories, driven by subsidiary Enzene Biosciences. Seven have been launched in , including Cetuxa ( ) in 2023 for and Pertuza ( ) in September 2025 for HER2-positive . OTC expansions include lines under vitamins and supplements, complementing the core branded generics in pain relief and .

Acquisitions and subsidiaries

Major acquisitions

In 2012, Alkem Laboratories acquired an active pharmaceutical ingredient () manufacturing facility from NORAC, Inc. in , to enhance its capabilities in specialty and ensure with U.S. regulations. This move strengthened the company's supply chain control for international markets, particularly supporting its () pipeline. The following year, in 2013, Alkem completed the purchase of a second U.S.-based API facility, further bolstering its manufacturing footprint abroad and facilitating greater integration into the generics ecosystem. These acquisitions collectively expanded Alkem's presence by providing dedicated U.S. sites compliant with FDA standards, reducing dependency on third-party suppliers. In 2014, Alkem acquired the Clindac-A brand, a topical treatment, from S.A. in , marking a strategic entry into the segment. This purchase allowed the company to leverage an established product to broaden its domestic therapeutic portfolio and capture market share in skincare s. By 2015, Alkem acquired a U.S. formulation manufacturing facility from Long Pharmaceuticals LLC, including its R&D capabilities, to accelerate its generics launch in the American market. The facility specialized in semi-solids, liquids, and nasal products, enabling Alkem to diversify its export offerings and meet FDA requirements more efficiently. In 2025, Alkem transferred its trade generics business to its wholly-owned subsidiary, Alkem Wellness Limited, via a slump sale effective , integrating operations to streamline focus on core activities. This restructuring aimed to enhance operational agility and synergies within the generics division, supporting broader growth in domestic and international segments.

Key subsidiaries

Alkem Laboratories operates a network of key subsidiaries that enhance its global reach, specialization in generics, biosimilars, and wellness products, and commitment to digital health and corporate social responsibility as of 2025. These entities play pivotal roles in diversifying operations beyond the parent company's core activities in India. Ascend Laboratories LLC serves as Alkem's primary marketing arm in the United States, focusing on the commercialization of generic pharmaceuticals. Established as a wholly owned subsidiary, it manages a robust portfolio of products, with Alkem's research centers having filed over 140 Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA) to support its growth in the generics market. Ascend has positioned Alkem among the fastest-growing generic drug companies in the U.S., contributing significantly to international expansion through sales in key therapeutic areas like cardiovascular and anti-infectives. In October 2025, Ascend initiated a voluntary recall of certain Atorvastatin Calcium tablets due to failed dissolution specifications, as announced by the FDA. Pharmacor Limited, operating across multiple international markets including , , , and , functions as a wholly owned dedicated to the distribution and marketing of generic and over-the-counter (OTC) formulations. In , Pharmacor emphasizes affordable, high-quality medicines for pharmacies and hospitals, leveraging partnerships to broaden access to essential healthcare products. Its operations in , particularly through Pharmacor Ltd. in , strengthen Alkem's presence in emerging markets by focusing on generics that address local health needs such as infectious diseases. Complementing international efforts, Pharmaceuticals Pvt Ltd handles domestic formulations and OTC products as a key of Alkem. Founded in and integrated into the group, manufactures and markets a diverse range of pharmaceutical formulations, including antibiotics, analgesics, and nutraceuticals, primarily for the market. With headquarters in and multiple manufacturing units compliant with (WHO) standards, it supports Alkem's domestic growth by providing cost-effective solutions in chronic and acute therapies. Enzene Biosciences Limited, a specializing in research and development of biosimilars and biologics, drives Alkem's innovation in complex molecules. Based in with a U.S. established in 2024, Enzene has commercialized several biosimilars, including for and , for neovascular age-related , and partnerships for treatments. Its pipeline emphasizes monoclonal antibodies like and , enabling Alkem to enter high-value biologics markets globally. Indchemie Health Specialities Pvt Ltd operates as Alkem's nutraceuticals and division, focusing on specialized formulations in areas like gynecology, orthopedics, , and infectious diseases. Established in 1986, this subsidiary develops and markets products that blend pharmaceuticals with nutritional supplements to promote preventive health, including dermatological and solutions. Its emphasis on nutraceuticals supports Alkem's diversification into , addressing growing demand for integrated health products in domestic and select international markets. Connect 2 Clinic Private Limited represents Alkem's arm, providing and outpatient solutions launched in 2020 to expand access amid the . As a wholly owned , it offers an end-to-end platform for consultations, records, and , connecting over 20,000 verified doctors with patients across . Post-2020 expansions have integrated AI-driven features for seamless in-clinic and online services, enhancing Alkem's role in of healthcare delivery. The Alkem Foundation, Alkem's (CSR) entity, advances community health, , and initiatives as a wholly owned . In 2025, it committed 20-25% of its seven-year CSR obligations to establishing an advanced research center at for and , underscoring its focus on impactful social investments. The foundation's programs, including healthcare access in underserved areas, align with Alkem's goals. Collectively, these subsidiaries bolster Alkem's operations, with international units contributing approximately 29.8% to total sales in 2025, reflecting their strategic importance in revenue diversification and global competitiveness.

Financial performance

Revenue and profitability

Alkem Laboratories achieved consolidated revenue from operations of ₹12,965 (US$1.5 billion) in 2025, reflecting a modest 2.3% year-over-year growth driven by steady domestic demand. Net profit after tax rose 20.6% to ₹2,166 , underscoring improved operational despite muted top-line expansion. Earnings before interest, tax, depreciation, and amortization (EBITDA) reached ₹2,512 , with margins expanding to 19.4% from 17.7% in the prior year, bolstered by cost optimization initiatives. Revenue breakdown highlighted the domestic market's dominance, contributing 70% of total sales through chronic and acute therapeutic segments, while international operations accounted for the remaining 30%. In the fourth quarter of FY2025, grew 7.1% year-over-year to ₹3,144 , with profit after tax increasing 4.2% to ₹306 amid enhanced operational efficiencies and outperformance in areas like and gynecology. Key drivers of profitability included stringent cost controls, which mitigated raw material volatility, and accelerated in non-U.S. markets such as and following the disruptions. Post-COVID recovery played a pivotal role, particularly in acute therapies like antibacterials, which faced initial setbacks but achieved modest rebound by FY2023 onward. From FY2015 to FY2025, Alkem's expanded from approximately ₹5,400 to over ₹12,900 , representing a of about 9%, with accelerated profitability post-2020 reflecting resilient demand recovery in both domestic and channels.

Market position and stock information

Alkem Laboratories maintains a significant presence in the pharmaceutical sector, with a of approximately $6.9 billion as of June 30, 2025, based on a closing share price of ₹4,939 and 119.56 million , converted at the prevailing USD/INR of 85.69. This valuation positions the company among the top-10 pharmaceutical firms by , where its FY2025 reached ₹129,645 million (approximately $1.54 billion), underscoring its scale in a competitive landscape dominated by like and . The company's competitive strengths lie in its robust domestic branded portfolio, which drives over 70% of revenues and includes leading products in therapeutic areas like and anti-infectives, contributing to a 4.1% in India's domestic formulations market as of the first nine months of FY2025, making it the fifth-largest player. Internationally, Alkem demonstrates leadership in generics through its wholly-owned subsidiary Ascend Laboratories LLC, which is recognized among the fastest-growing entities in sales in the market. This dual focus on branded domestic offerings and export-oriented generics provides a diversified base amid global opportunities in affordable healthcare solutions. Alkem Laboratories has been publicly listed on the (BSE) and National Stock Exchange (NSE) since December 23, 2015, following its . As of June 2025, its enterprise value stood at US$6.57 billion, reflecting a stable financial structure with low debt levels. Key valuation metrics include a trailing price-to-earnings (P/E) of 25.4, indicating moderate growth expectations relative to peers, while the company has maintained a consistent with a of 0.79% as of October 2025, including payouts of ₹37 per share (interim) in February 2025 and ₹8 per share (final) in August 2025, supported by a payout of approximately 22%. In the broader industry context, Alkem operates within India's domestic pharmaceutical market, valued at around ₹2.4 crore in 2025 and growing at 7-9% annually, where its emphasis on generics positions it well to capitalize on global expirations—known as patent cliffs—that enable affordable alternatives to branded drugs, particularly in therapies like antidiabetics and cardiovascular treatments. This focus aligns with the sector's shift toward volume-driven growth in emerging markets. Looking ahead, analyst reports project Alkem's revenue to grow at 9.3% per annum from 2025 to 2028, fueled by domestic market expansion, international diversification beyond the (including new ventures in ), and chronic segment penetration, with the overall Indian pharma industry expected to reach US$120-130 billion by 2030 at a of 10-12%.

References

  1. [1]
    Alkem - About Alkem
    ### Summary of Alkem Laboratories
  2. [2]
    Alkem Laboratories Limited (ALKEM.NS) Stock Price, News, Quote ...
    Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical ...<|control11|><|separator|>
  3. [3]
    Alkem Laboratories: From pharma distribution to a Rs 11,600 crore ...
    Nov 16, 2023 · August 8, 1973, remains etched in Basudeo Narayan Singh's memory. “It was the day we got our company registration licence in Mumbai, and Alkem ...
  4. [4]
    Milestones - Alkem Laboratories
    The inspirational journey of Alkem began in 1973, and ever since its inception, it has changed the world of pharmaceuticals through its contributions.Missing: history | Show results with:history
  5. [5]
    Alkem Laboratories 2025 Company Profile - PitchBook
    Alkem Laboratories ; Average Volume 163K ; EPS $2.25 ; HQ Location. Mumbai, India ; Employees. 22,833 as of 2025 ; Primary Industry. Pharmaceuticals.
  6. [6]
    Top 10 pharma companies in India by market cap [2025]
    Jun 19, 2025 · Top 10 pharma companies in India by market cap ; #9, Alkem Lab Limited, 0.63 lakh crore, Mumbai, Maharashtra ; #10, Aurobindo Pharma Limited, 0.60 ...
  7. [7]
    Key Contacts - Alkem Laboratories
    Registered Office and Corporate Office: Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai – 400 013, Maharashtra, India. +91 22 3982 99 99 · contact@alkem ...
  8. [8]
    Shareholding Pattern - Alkem Laboratories
    ALKEM LABORATORIES LIMITED. BSE3213.15. -0.26 %(-8.40). NSE3214.35. -0.33 %(-10.80). Note: The displayed data may not be real time due to streaming delays.<|control11|><|separator|>
  9. [9]
    Alkem Laboratories
    Alkem Labs has 19 manufacturing units, 800 brands, business footprint in 40 countries, and many achievements to its credit. Click here to learn more.Rx ProductsUnited StatesAbout AlkemKey ContactsDiscover thePerfect Career
  10. [10]
    [PDF] Shape the Future - your Strapi app - Alkem Laboratories
    Mar 27, 2024 · Financial Statements of the Company for financial year ended 31 March, 2025. ... Financial assets: Business model assessment. The Company ...
  11. [11]
    Overview - Alkem Laboratories
    Alkem markets and sells products in the USA, Australia, Europe, Southeast Asia, Latin America, Africa, and CIS. Click here to learn more.
  12. [12]
    Alkem Laboratories founder Samprada Singh passes away
    Jul 27, 2019 · Drug firm Alkem Laboratories on Saturday said its Founder and Chairman Emeritus Samprada Singh has passed away.
  13. [13]
    Singh family - Forbes
    The Singh family inherited a majority stake in generics maker Alkem Laboratories, after company founder Samprada Singh passed away in July 2019.
  14. [14]
    Sandeep Singh, Alkem Laboratories Ltd: Profile and Biography
    CURRENT POSITION. Managing Director, Alkem Laboratories Ltd ; TENURE AT CURRENT POSITION. 10/2017-PRESENT ; PREVIOUS POSITION. Joint Managing Director, Alkem ...
  15. [15]
    Meet B.Com graduate who leads Rs 58766 crore pharma company ...
    Dec 25, 2023 · The 40-year-old spearheads the domestic as well as the international operations of the organization.
  16. [16]
    Alkem Laboratories Appoints Dr Vikas Gupta As New CEO
    Sep 15, 2023 · Dr Vikas Gupta holds an M.B.B.S degree from the University College of Medical Sciences, Delhi University. He has over two decades of experience ...Missing: background | Show results with:background
  17. [17]
    Vikas Gupta: Positions, Relations and Network - MarketScreener
    Vikas Gupta is currently the Chief Executive Officer at Alkem Laboratories Ltd. He holds a doctorate degree from the University of Delhi.
  18. [18]
    Board of directors - Alkem
    Board of Directors · Mr. Basudeo N. Singh · Mr. Sandeep Singh · Mr. Mritunjay Kumar Singh · Mrs. Madhurima Singh · Mr. Sarvesh Singh · Mr. Srinivas Singh · Mr.
  19. [19]
    Alkem Laboratories Limited: Governance, Directors and Executives ...
    Nominating Committee, 2020-03-31. Diwakar Gupta. 71 year. Audit Committee Chair. Audit Committee, 2022-12-31. Compensation Committee, 2022-12-31.
  20. [20]
    Diwakar Gupta Joins Alkem Board As Independent Director
    Jun 19, 2025 · Alkem Laboratories Limited announced that its Board of Directors has approved the appointment of Diwakar Gupta as an Independent Director (Additional Director)<|separator|>
  21. [21]
    Meet Basudeo Singh, The Man Who Turned Rs 5 Lakh Pharma ...
    Dec 8, 2023 · He is the executive chairman of Alkem Laboratories. Basudeo hails from Bihar, and was once a professor. He completed his graduation and post- ...
  22. [22]
    How Alkem's 83-year-old founder is remaking India's 4th-largest ...
    Jun 18, 2024 · Hailing from Okari, a remote village in Jehanabad district of Bihar, Singh and his brother, Samprada, moved to Mumbai in 1973 to start Alkem ...
  23. [23]
    Composition of Committees - Alkem Laboratories
    Name of the Director, Designation in the Committee. Mr. Narendra Kumar Aneja, Chairperson. Mr. Sandeep Singh, Member. Mr. Mritunjay Kumar Singh, Member.
  24. [24]
    [PDF] Corporate Governance Report - Alkem Laboratories
    The constitution of the Audit Committee is in compliance with the provisions of Section 177 of the Act and Regulation. 18 of the SEBI LODR Regulations.
  25. [25]
    [PDF] ESG Policy - Alkem Laboratories
    In our endeavour towards sustainability journey, we strive to integrate the leading practices on. Environmental, Social, and Governance (ESG) aspects into our ...
  26. [26]
    Sustainability - Alkem Laboratories
    Our ESG (Environment, Social, and Governance) initiatives reflect our commitment to turning this vision into a reality.
  27. [27]
    https://admin.alkemlabs.com/uploads/Alkem_Foundation_CSR_2024_25_Web_upload_file_SGAADS_30_10_2025_7bf975acd2.pdf
  28. [28]
    [PDF] ALKEM LABORATORIES LIMITED - J.P. Morgan
    Jul 15, 2010 · Alkem Laboratories Limited (“Company”) was incorporated as a private limited company 'Alkem Laboratories Private Limited' on August 8, 1973 ...<|control11|><|separator|>
  29. [29]
    Founders' Story - Alkem Laboratories
    Alkem's founders are Mr. Samprada Singh, who established the company in 1973, and Mr. Basudeo N. Singh, his co-founder who supported him.
  30. [30]
    [PDF] The Emergence of India's Pharmaceutical Industry and Implications ...
    May 28, 2007 · With changes in India's patent laws in the early 1970s, Indian drug producers became experts in. 'reverse engineering' and increased its ...Missing: Alkem | Show results with:Alkem
  31. [31]
    Connect2Clinic
    Connect2Clinic, an exceptional digital initiative pioneered by Alkem Labs, is dedicated to transforming the management of healthcare practices.
  32. [32]
    Manufacturing Facilities - Alkem Laboratories
    Alkem has an extensive manufacturing footprint which has a total of 18 manufacturing facilities ... Dividend Details. Careers. Employee Value Proposition ...
  33. [33]
    Ophthalmology - Alkem Laboratories
    Alkem Laboratories announces its entry into the field of Ophthalmology with the launch of an extensive portfolio of affordable and quality eye care products.
  34. [34]
    Supply Chain Data Of Alkem Laboratories Ltd Company Profile
    The company's top sourcing countries are united states, germany and spain, and top export markets are nepal, united states and australia. package. alkem ...Missing: raw | Show results with:raw
  35. [35]
    [PDF] Sustaining - Alkem Laboratories
    Alkem Laboratories is a leading Indian Pharmaceutical company with global presence in more than 40 countries. Founded in 1973, the. Company has grown to become ...
  36. [36]
    [PDF] Charting - Alkem Laboratories
    Apr 29, 2024 · Today, we stand as a formidable global pharmaceutical company with a robust presence across multiple therapeutic areas and geographies. We ...
  37. [37]
    Alkem Laboratories - Wikipedia
    Alkem Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. Specialising in generics and speciality pharmaceuticals.
  38. [38]
    [PDF] Alkem reports 7.1% YoY revenue growth in Q4FY25
    May 29, 2025 · Apart from India, the company has a meaningful presence in the US, Latin America, Australia, and several other Asian countries. “Inspiring ...
  39. [39]
    United States - Alkem Laboratories
    Registered Office and Corporate Office: Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai – 400 013, Maharashtra, India. +91 22 3982 99 99 · contact@alkem.
  40. [40]
    Rx Products - Alkem Laboratories
    We have a wide range of products spanning multiple Therapeutic Areas (TA) such as Anti-infective, Gastroenterology, Pain Relief/Analgesic, Anti-diabetic ...Alkem's Competitive... · About Us · International Presence
  41. [41]
    [PDF] Strong Expanding to Newer Ones - Alkem Laboratories
    Acquired Enzene, a company engaged in the development of biosimilars in India. 2012. Acquired an API Manufacturing facility in the US. 2014. Acquired the ...<|separator|>
  42. [42]
    Alkem dares pharma sentiment with an IPO - Business Standard
    Nov 26, 2015 · The company acquired two API manufacturing units in 2012 and 2013. In 2015 Alkem acquired a formulation unit in the US. Rather than having ...
  43. [43]
    [PDF] Alkem Laboratories
    Acquired an API Manufacturing facility in the US. 2013. Acquired an API manufacturing facility in the US. 2014. Clavam (anti-bacterial) crossed Rs 2bn in terms ...
  44. [44]
    [PDF] Alkem Laboratories - Angel One
    Jan 3, 2017 · 2011 Acquisition of Enzene. 2012 Acquisition of an API Manufacturing facility in the USA. 2014 Acquisition of “Clindac-A” brand from Galderma ...
  45. [45]
    [PDF] Alkem Laboratories Ltd. - FundsIndia
    Nov 11, 2016 · In June 2015, the company acquired a formulation manufacturing facility along with its R&D capabilities from Long Pharmaceuticals LLC, in the US ...
  46. [46]
    Alkem Labs transfers trade generics business to its subsidiary Alkem ...
    Sep 26, 2025 · The transfer, originally intimated in December 2024, will be effective from October 1, 2025. Earlier this week, Alkem Labs received an order ...
  47. [47]
    Alkem Labs transfers trade generics business to Alkem Wellness
    Sep 27, 2025 · As per the terms of the agreement, the transfer will take effect on October 1, 2025. The rationale for slump sale is to achieve agility, better ...
  48. [48]
    Subsidaries - Alkem Laboratories
    Subsidaries ; Alkem Foundation, India, Wholly Owned Subsidiary ; Alkem Wellness Limited, India, Wholly Owned Subsidiary ; Alixer Nexgen Therapeutics Limited, India ...Missing: initiatives | Show results with:initiatives
  49. [49]
    Research & Development – Ascend Germany
    Alkem Laboratories' research and development center has filed over 140 ANDAs with the FDA in the US, nearly 60 products with the TGA in Australia.
  50. [50]
    [PDF] Pharmacor Pty Limited - Alkem Laboratories
    May 6, 2021 · Pharmacor is a rapidly-growing generic pharmaceutical company based in Sydney, Australia. Our focus is on bringing the best value to pharmacies ...
  51. [51]
    East Africa - Alkem Laboratories
    Pharmacor Ltd. is a wholly-owned subsidiary of Alkem in Kenya. Pharmacor Ltd. has been established as one of Kenya's strongest players in healthcare.
  52. [52]
    Cachet Pharmaceuticals
    We are engaged in manufacturing and marketing of a wide range of pharmaceutical formulations and nutraceuticals to meet the demands of domestic and ...About Us · Life At Cachet · Infrastrure · Therapy
  53. [53]
    Career - Cachet Pharmaceuticals
    Cachet Pharmaceuticals Private Limited, established in 1978 is a subsidiry of Alkem Laboratories Limited. Cachet with over 4 decades in the pharma industry ...
  54. [54]
    Enzene Biosciences launches biosimilar Adalimumab
    Enzene Biosciences Ltd. has announced that it has begun commercial supplies of Adalimumab for treating Ankylosis Spondylitis (AS) and Rheumatoid Arthritis (RA).
  55. [55]
    Enzene Biosciences launches its first manufacturing base in the US
    Jan 8, 2024 · Enzene is an innovation-driven biotech company and a subsidiary of Alkem ... Enzene enter an exclusive partnership for biosimilar ...
  56. [56]
    Oncology - Alkem Laboratories
    Alkem Oncology offers three biosimilar drugs i.e. Rituximab (Oncology), Bevacizumab (Advamab) and Trastuzumab (Hersima). All of these are monoclonal antibodies.
  57. [57]
    Indchemie Health Specialities Pvt. Ltd. | Pioneering Pharmaceutical ...
    Our expertise spans multiple therapy areas, including gynaecology, orthopedics, gastroenterology, nutraceuticals, and infectious diseases. We focus on ...
  58. [58]
    Corporate Social Responsibility - Alkem
    The Alkem Laboratories Corporate Social Responsibility vision and policy aspires to bring a fundamental change in people's quality of life.Missing: governance | Show results with:governance
  59. [59]
    [PDF] Investor Presentation Q4 & FY25 May 29, 2025
    May 29, 2025 · The Company has a presence mainly in Latin America, Australia and Europe. OTHER INTERNATIONAL BUSINESS UPDATE. 2,855. 3,661. Q4FY24. Q4FY25.<|separator|>
  60. [60]
    [PDF] Management Discussion & Analysis - Alkem Laboratories
    Apr 29, 2024 · In the five decades of its global presence, Alkem Laboratories (the. Company/Alkem) has solidified its footing as a global Indian generic.
  61. [61]
    Alkem Laboratories (ALKEM.NS) - Revenue - Companies Market Cap
    Revenue for Alkem Laboratories (ALKEM.NS) · Revenue in 2025 (TTM): $1.54 Billion USD · Revenue history for Alkem Laboratories from 2015 to 2025.
  62. [62]
    Alkem Laboratories Limited (ALKEM.NS) Stock Historical Prices ...
    Volume. Nov 7, 2025, 5,644.50, 5,687.50, 5,571.50, 5,668.50, 5,668.50, 226,721. Nov 6, 2025, 5,670.50, 5,704.00, 5,631.00, 5,643.50, 5,643.50, 152,300.
  63. [63]
    Alkem Laboratories Shares Outstanding - MLQ.ai | Stocks
    NS) as of October 30th, 2025: According to Alkem Laboratories's latest financial reports, the company's current number of shares outstanding is 119.56M. The ...
  64. [64]
    U.S. Dollar-Indian Rupee History: 2025 - Pound Sterling LIVE
    Daily USD/INR rates for 2025, including the day's high, low, open, close ... Monday 30 June 2025 (30/06/2025). 85.4943. 85.6992. 85.9211. 85.4604. 85.6908.
  65. [65]
    Alkem Laboratories Ltd (BOM:539523) Q4 2025 Earnings Call ...
    May 30, 2025 · Total Revenue from Operations (FY25): INR 129,645 million, a Y-o-Y growth of 2.3%. · Q4 Revenue from Operations: INR 31,438 million, with growth ...Missing: automation | Show results with:automation
  66. [66]
    Alkem Laboratories Ltd share price | About Alkem Lab | Key Insights
    Alkem Lab · Mkt Cap: 67775 Crore (down -0.67% in 1 year) · Revenue: 13304 Cr · Profit: 2333 Cr · Promoter holding has decreased over last quarter: -1.84% ...
  67. [67]
    Alkem Laboratories IPO Date, Price, GMP, Review, Details
    The shares got listed on BSE, NSE on Dec 23, 2015. Alkem Laboratories IPO price band is set at ₹1050.00 per share . The lot size for an application is 14 ...
  68. [68]
    Alkem Laboratories (ALKEM.NS) - P/E ratio - Companies Market Cap
    P/E ratio for Alkem Laboratories (ALKEM.NS) · P/E ratio as of October 2025 (TTM): 25.4 · P/E ratio history for Alkem Laboratories from 2015 to 2025.
  69. [69]
    Alkem Laboratories Limited (ALKEM.NS) - Yahoo Finance
    Find out all the key statistics for Alkem Laboratories Limited (ALKEM.NS), including valuation measures, fiscal year financial statistics, trading record, ...
  70. [70]
    [PDF] Indian Pharmaceutical Market Quarterly Insights – Q2 2025(Apr-Jun)
    Q2 2025 saw higher single digit growth led by Chronic segment and MNCs, with a market size of 61K INR Cr, 9% growth over Q2 24. Chronic segment grew 10% and ...
  71. [71]
    Alkem Laboratories Future Growth
    Alkem Laboratories is forecast to grow earnings and revenue by 4.4% and 9.3% per annum respectively. EPS is expected to grow by 4.1% per annum. Return on equity ...Missing: 2025-2030 | Show results with:2025-2030
  72. [72]
    Healing the World: A Roadmap for Making India a Global Pharma ...
    The Indian pharma market, currently valued at $55 billion, is expected to reach $120 billion to $130 billion by 2030 and to approach $450 billion by 2047. In ...Executive summary · Megatrends shaping Indian... · Indian pharma exports: An...